<DOC>
	<DOCNO>NCT01042301</DOCNO>
	<brief_summary>The `` Lymphoscreen '' study aim characterize precisely ( phenotypes/cytokines/functions ) CD8+ T cell response type 1 Diabetes identify biomarkers disease . Such marker need refine type 1 Diabetes diagnosis/prognostic , design new therapeutic approach target autoreactive CD8+ T cell . An original approach use DNA immunization humanize mouse allow u identify relevant CD8 epitopes derive GAD65 IA-2 beta cell autoantigens . The aim : ( ) identify exhaustively epitopes recognize autoreactive CD8+ T lymphocytes type 1 Diabetes follow islet pancreas graft human ; ( ii ) identify pathogenic CD8+ T cell pattern profile relate type 1 Diabetes pathogenesis evolution ; ( iii ) correlate CD8+ autoreactive T cell response autoantibody responses new cellular ( CD4+ T cell peripheral cell miRNA ) humoral marker disease ( serum miRNA ) .</brief_summary>
	<brief_title>Profiling Original Cellular Humoral Biomarkers Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Inclusion criterion : least , 50 patient `` recent '' type 1 diabetes , 30 patient longterm type 1 diabetes , 10 patient Latent Autoimmune Diabetes , 10 subject risk diabetes , 20 type 1 diabetic patient pancreatic graft Langerhans islet graft . 50 healthy subject pair HLA class I age Those subject respect follow criterion : Age 7 70 Caucasian Affiliated national insurance scheme Written inform consent obtain For child , write informed consent require two parent . Noninclusion criterion : Age strictly inferior 7 strictly superior 70 year old Pregnancy Secondary diabetes No write inform consent</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>